GB8618811D0 — Sustained release ibuprofen formulation
Assigned to Teva UK Ltd · Expires 1986-09-10 · 40y expired
What this patent protects
The present invention provides a sustained release alpha -4-(2-methylpropyl)benzene acetic acid (Ibuprofen) formulation comprising sufficient granules to provide a predetermined dose or number of doses of Ibuprofen, each granule having a diameter between 0.5 and 2.0 mm and compr…
USPTO Abstract
The present invention provides a sustained release alpha -4-(2-methylpropyl)benzene acetic acid (Ibuprofen) formulation comprising sufficient granules to provide a predetermined dose or number of doses of Ibuprofen, each granule having a diameter between 0.5 and 2.0 mm and comprising: a) a core containing l00 parts of Ibuprofen and from l0 to 70 parts of a microcrystalline cellulose; and b) a coating covering substantially the whole surface of the core and comprising l00 parts of a water insoluble but water swellable acrylic polymer and 20 to 70 parts of a water-soluble hydroxylated cellulose derivative, the weight of the coating being from 5 to 20% of the weight of the core. i
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.